July 21, 2017
2 min read
Save

New visual field app automates classification of glaucoma severity

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new application that provides automated classification of visual field severity may serve as a new guide for managing glaucoma and estimating and monitoring progression.

Perspective from Lisa M. Young, OD, FAAO

The Glaucoma Staging Application (GSA) is based on the modified University of São Paulo Glaucoma Visual Field Staging System. It is designed to connect to Humphrey perimeters to automatically provide classification of severity, location and topographic extent of glaucoma damage based on visual field data.

In a study, 612 visual fields of 64 eyes of 32 patients were analyzed by the GSA. All visual fields were also independently analyzed by experienced ophthalmologists, and outcomes were compared.

The output of the GSA exactly coincided with the expert’s grading. The system also showed excellent reproducibility: The same classification was obtained when the test was repeated 1 week later, again involving GSA classification and independent analysis by the same ophthalmologist.

The GSA proved capable of classifying a wide range of visual field severity. Early damage was detected in 178 visual eyes (29%), moderate damage in 148 eyes (24%) and severe damage in 156 eyes (25%). No significant damage was present in 130 eyes (21%).

According to the authors, this application could help both clinicians and researchers to evaluate the extent of glaucomatous damage and its location and assess the risk of progression.

“Our study is a proof of concept that, if accepted by clinicians and researchers, could become a useful tool to objectively analyze visual fields,” they wrote. “It is our intent to make this application widely available so it can be translated into practical usefulness in clinical and research settings.” – by Michela Cimberle

Disclosure: The authors reported no relevant financial disclosures